High-density lipoproteins, platelets and the pathogenesis of atherosclerosis - PubMed (original) (raw)
Review
High-density lipoproteins, platelets and the pathogenesis of atherosclerosis
Jerzy-Roch Nofer et al. Clin Exp Pharmacol Physiol. 2010 Jul.
Abstract
1. Prospective and interventional studies demonstrate an inverse relationship between plasma high-density lipoprotein (HDL)-cholesterol and the incidence of coronary artery disease. Although the atheroprotective effects of HDL are usually attributed to the reverse cholesterol transport, in which HDL shuttles cholesterol from cells in the arterial wall to the liver, other mechanisms are also under investigation. 2. Platelets are involved in both the initiation and progression of atherosclerotic lesions. In addition, the formation of thrombi over ruptured atherosclerotic plaques results in the narrowing or complete occlusion of coronary arteries. Current experimental evidence suggests that HDL may exert antiplatelet effects and thereby counteract the development of atherothrombotic vascular disease. 3. In vitro studies show that HDL inhibits agonist-stimulated platelet aggregation, fibrinogen binding, granule secretion and liberation of thromboxane A(2). Inhibitory effects of HDL are mediated, in part, by scavenger receptor type B1 and/or the apolipoprotein E receptor apoER2/LRP8 and are linked to the induction of intracellular signalling cascades encompassing stimulation of protein kinase C, cytoplasmatic alkalization and generation of nitric oxide. 4. Populational studies demonstrate that there is an inverse association between plasma HDL levels and recurrent venous thromboembolism. In addition, HDL-cholesterol has been identified as an independent predictor of acute platelet thrombus formation. The administration of reconstituted HDL particles in humans attenuates ex vivo platelet activation. 5. The present review summarizes recent advances in understanding HDL-platelet interactions and discusses the potential use of HDL-like particles in the therapy of thrombosis.
Similar articles
- Current understanding of the role of high-density lipoproteins in atherosclerosis and senescence.
Nofer JR, Walter M, Assmann G. Nofer JR, et al. Expert Rev Cardiovasc Ther. 2005 Nov;3(6):1071-86. doi: 10.1586/14779072.3.6.1071. Expert Rev Cardiovasc Ther. 2005. PMID: 16292998 Review. - [Antiatherogenic effect of high density lipoprotein].
Turczyn B, Skoczyńska A. Turczyn B, et al. Postepy Hig Med Dosw. 2002;56(4):499-520. Postepy Hig Med Dosw. 2002. PMID: 12418415 Review. Polish. - High-density lipoproteins, inflammation and oxidative stress.
Tabet F, Rye KA. Tabet F, et al. Clin Sci (Lond). 2009 Jan;116(2):87-98. doi: 10.1042/CS20080106. Clin Sci (Lond). 2009. PMID: 19076062 Review. - Blockade of scavenger receptor class B type I raises high density lipoprotein cholesterol levels but exacerbates atherosclerotic lesion formation in apolipoprotein E deficient mice.
Kitayama K, Nishizawa T, Abe K, Wakabayashi K, Oda T, Inaba T, Amemiya Y. Kitayama K, et al. J Pharm Pharmacol. 2006 Dec;58(12):1629-38. doi: 10.1211/jpp.58.12.0010. J Pharm Pharmacol. 2006. PMID: 17331327
Cited by
- Modulation of the Cellular microRNA Landscape: Contribution to the Protective Effects of High-Density Lipoproteins (HDL).
Graham A. Graham A. Biology (Basel). 2023 Sep 13;12(9):1232. doi: 10.3390/biology12091232. Biology (Basel). 2023. PMID: 37759631 Free PMC article. Review. - Emerging therapeutic strategies to enhance HDL function.
Redondo S, Martínez-González J, Urraca C, Tejerina T. Redondo S, et al. Lipids Health Dis. 2011 Oct 10;10:175. doi: 10.1186/1476-511X-10-175. Lipids Health Dis. 2011. PMID: 21985435 Free PMC article. Review. - Enhanced lipid peroxidation and platelet activation as potential contributors to increased cardiovascular risk in the low-HDL phenotype.
Vazzana N, Ganci A, Cefalù AB, Lattanzio S, Noto D, Santoro N, Saggini R, Puccetti L, Averna M, Davì G. Vazzana N, et al. J Am Heart Assoc. 2013 Apr 4;2(2):e000063. doi: 10.1161/JAHA.113.000063. J Am Heart Assoc. 2013. PMID: 23557750 Free PMC article. - Fibrinogen as a key regulator of inflammation in disease.
Davalos D, Akassoglou K. Davalos D, et al. Semin Immunopathol. 2012 Jan;34(1):43-62. doi: 10.1007/s00281-011-0290-8. Epub 2011 Oct 31. Semin Immunopathol. 2012. PMID: 22037947 Review. - Relation between high density lipoprotein particles concentration and cardiovascular events: a meta-analysis.
Wu Y, Fan Z, Tian Y, Liu S, Liu S. Wu Y, et al. Lipids Health Dis. 2018 Jun 19;17(1):142. doi: 10.1186/s12944-018-0732-6. Lipids Health Dis. 2018. PMID: 29921280 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical